GTx, Inc. (Nasdaq: GTXI) announced the submission of a New Drug Application with the U.S. Food and Drug Administration (FDA) for toremifene 80 mg, an oral choose
ive estrogen receptor modulator (SERM), for the prevention of bone fractures in men with prosay
cancer on androgen deprivation therapy (ADT). “ADT has helped improve survival for men with advanced prosay
cancer.
source : http://www.medicalnewstoday.com
Details :
Submited at Tuesday, January 6th, 2009 at 2:00 pm on Orthopaedic by madison
Comment RSS 2.0 - leave a comment - trackback
Leave a Reply